Drugs / Petiveria alliacea
Petiveria alliacea
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05587088 | Dec 2022 → Mar 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, colorectal neoplasm, gastric cancer +1 | Hospital Universitario San Ignacio | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Petiveria alliacea | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05587088 ↗ |
| Known as | Anamú | “Petiveria alliacea (Traditional name: Anamu) could inhibit glycolysis and OXPHOX modulating tumor metabolism, making it a potential treatment for tumors with altered metabolism.” PMID 37563608 ↗ Aug 20231“Anamú, Petiveria alliacea, has been used by traditional medicine to treat leukemia and breast cancer.” NCT05587088 ↗ |
| Known as | Esperanza | “This clinical study aims to evaluate the safety and efficacy of a standardized Anamu phytomedicine called Esperanza in treating gastric tumors and acute leukemias.” PMID 37563608 ↗ Aug 2023 |
| Modality | Traditional medicine (herbal / TCM) | “a standardized Anamu phytomedicine called Esperanza” PMID 37563608 ↗ Aug 2023 |